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CONTROVERSY OF NEW STAGING SYSTEM
Peter Goldstraw  
Thoracic Surgery, Royal Brompton Hospital, London/UNITED KINGDOM
Deficiencies in the 7th edition of TNM for Lung Cancer The 7th Edition of TNM for 
Lung Cancer was an enormous improvement on previous revisions. Never before has the 
lung cancer community been so well informed about proposed changes or presented with 
the detailed supportive data. The data base used was many times larger than any previous 
one and for the first time the data was collected from international sources, including 
patients treated by all modalities of care. The detailed analysis included validation, both 
internal and external, to a unique degree. However, the IASLC International Staging 
Project is striving to improve the classification further in the 8th and future editions. 
Central to this is the collection of additional data, with a wider geographical spread, better 
balance of treatment modalities and with prospective data collection and an expanded data 
set. This will be used to explore the following: 
Prospective validation of the new descriptors included in the 7th edition.
a) New tumour size cut points were introduced at, 2, 5 and 7cms and the previous 3cm cut 
point was retained. 
b) An internationally agreed definition of visceral pleural invasion (VPI) was introduced 
which will now allow closer study of the prognostic impact of VPI and other factors such 
as tumour size. 
c) Tumours associated with additional tumour nodules (ATN) in the lobe of the primary 
were re-classified as T3. If associated with N0 disease these became stage IIB and with N1-2 
they are now 
stage IIIA disease. We need to examine if these changes apply for such cases with multiple 
ATNs and ATN within the lobe of the primary but remote from the primary tumour. 
This process will be facilitated by the clearer definition of ATN and synchronous primary 
tumours provided within the 7th edition. 
d) Similarly tumours associated with ATNs in other ipsilateral lobes were re-classified as 
T4 disease. e) Tumours classified as T4 due to local invasion and associated with N0-1 have 
been re-classified as stage IIIA and this requires prospective validation. 
f) Carcinoid tumours are now included within the TNM classification. We need to evaluate 
if this applies to the whole spectrum of neuro-endocrine tumours and if some descriptors 
need to be tailored specifically for tumours in these categories; i.e. have we the best size cut-
points, how do we classify multiple nodules associated with Diffuse Idiopathic Pulmonary 
Neuroendocrine Hyperplasia? The indolent nature of typical carcinoid tumours requires 
the collection of disease-specific survival data. 
Validation of descriptors carried forward from earlier editions.
a) No guidance has ever been provided on how “size” of the primary tumour should be 
measured, by single dimension, multiple or volumetric analysis. This is especially pertinent 
in the era of low-dose CT screening. The new adenocarcinoma classification has raised the 
question as to whether one should measure the size of the solid component, disregarding 
any GGO component. 
b) Infrequently used T descriptors such as the proximal limit of the tumour within the 
airway and the extent of atelectasis/obstructive pneumonitis should be validated or 
expunged from the classification. 
c) Direct invasion of an adjacent lobe, across or below the fissure, is classified as T2 without 
any supportive data. 
d) Tumours invading the mediastinum were divided into T3 and T4 in the mid ‘80’s on 
the basis of which organ was involved. This division was carried forward in the 7th edition 
but requires validation. e) The N categories included in earlier editions were validated for 
the first time using the IASLC data base, and were carried forward into the 7th edition. 
However, more detailed assessment of the N categories; the relationship between the 
lobe of the primary and the pattern of nodal spread, the influence of nodal bulk and the 
multiplicity of nodal sites could not be evaluated as 2 distinct nodal charts were in use 
during the period of data collection. The introduction of an internationally accepted, 
unified nodal chart should allow more detailed assessment of the N categories in future 
editions. 
f) The prognostic impact of pleural effusion associated with small-cell-lung cancers was 
not clear in the 7th edition and requires closer study. 
Validation of “proposals for testing” introduced in the 7th edition.
a) The proposal to include an additional “R” category of “R0(un)” to include cases 
classified as pN0 when less that the recommended number of nodes had been removed 
and examined histologically, or if the highest mediastinal node removed was found to be 
positive requires validation. 
b) The finding of positive cytology on pleural lavage taken as a first step during 
thoracotomy has been shown to be an independent and adverse prognostic factor. The size 
of this effect and the resultant relapse patterns require further study. 
c) The sub-division of VPI into “PL” categories allows scrutiny of the accepted definition 
and an evaluation of the prognostic impact of depth of invasion. 
d) A sub-division of the T3 category according to the depth of invasion (T3a-T3c) was 
proposed for future evaluation. 
e) A new classification for clinically detected lymphangitis carcinomatosis (cLy0-4) has 
been proposed and should be evaluated. 
f) The concept of nodal “zones” was introduced, defined and included in the IASLC nodal 
chart. One needs to assess if this was found to be of value to oncologists, more used to 
assessing bulky nodal disease which might transgress the boundaries of nodal “stations”. 
The suggestion that the bulk of nodal disease is of greater prognostic impact than the 
anatomical position of the involved nodes was suggested by the finding that cases in which 
there was involvement of a single N2 zone had a similar 
prognosis to cases in which there was involvement of multiple N1 zones following complete 
resection. This requires more detailed study, including clinically staged cohorts. 
g) The prognostic impact of the burden of metastatic disease has been assessed by 
proposing that for M1b cases one collects data on the number of metastatic sites and the 
number of deposits at each site. The interaction of site and tumour burden may be of 
interest. 
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CLINICAL APPLICATION OF NEW (7TH) TNM STAGING SYSTEM 
FOR LUNG CANCER
Hisao Asamura  
Division Of Thoracic Surgery, National Cancer Center Hospital, Tokyo/JAPAN
The definitive diagnosis of the stage of the disease before starting the treatment is a 
crucial part in dealing with the patients with lung cancer. Three factors, stage, histology, 
and physical condition of the patients, determine the possible choice of the treatment. 
Therefore, the quality of the assessment of stage is reflected in the quality of the treatment 
chosen. A new (7th) staging system for lung cancer has been on act by UICC and AJCC 
simultaneously since january, 2010. This classification has been based on the proposal by 
staging committee of IASLC (International Association for the Study of Lung Cancer). For 
the present revision, the IASLC initiated a “staging project” early, and accumulated data of 
more than 100,000 patients from all the continents. The agenda was established through 
the simulation and validation upon these database, in which the new categorization of 
T according to tumor diameter and satellite nodules, the creation of new lymph node 
chart, and the new stage grouping are characterized. The policy of assessing the stage of 
the disease is termed as “minimal staging”, which minimizes the diagnostic modalities 
necessary to determine the stage. Diagnostic modalities are histology and stage-specific. 
In case of an asymptomatic patient with solitary nodule without nodal involvemnet, the 
further investigation for the possible distant metastases such as brain MRI is not usually 
indicated. The invasive technique such as mediastinoscopy is being replaced by PET scan 
and EBUS technique very recently. The affordable, reliable work-up must be the initial, 
important part of the care for the patients with lung cancer.
Keywords: staging, TNM classification, Surgery, Prognosis
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BIOMARKERS FOR ANTI-ANGIOGENIC THERAPY
Millie Das1, Heather Wakelee2  
1Stanford University School Of Medicine, Stanford/CA/UNITED STATES OF AMERICA, 
2Stanford School Of Medicine, Stanford/CA/UNITED STATES OF AMERICA
Predictive biomarkers for anti-angiogenesis agents have remained elusive. The 
development of bevacizumab and other vascular endothelial growth factor (VEGF) 
targeted drugs has been slowed by this limitation and the true potential of these agents 
will not be realized until better biomarkers have been discovered. The development of 
hypertension is correlated with response to VEGF agents. This was initially noted in 
trials of renal cell carcinoma in which a strong connection was seen between onset of 
hypertension and response to VEGF targeted drugs.1An association with development of 
hypertension and clinical benefit was also seen in the landmark non-small cell lung cancer 
(NSCLC) trial E4599, which randomized patients with advanced NSCLC to receive first-
line carboplatin/paclitaxel with or without the VEGF targeted antibody bevacizumab.2 
This trial demonstrated a substantial increase in response rate (more than double), 
increased progression-free survival (PFS) and a statistically significant improvement 
in overall survival (OS) (10.3 compared to 12.3 months) in the bevacizumab arm, with 
onset of hypertension associated with more pronounced benefit. However, surrogates 
for the development of hypertension have yet to be discovered and this response can 
therefore only be assessed after initiation of therapy. Serum and plasma markers, including 
circulating VEGF levels, have been studied extensively. In E4599, high baseline plasma 
VEGF levels were found to correlate with higher response to bevacizumab but did not 
predict for a survival benefit.3 E4599 investigators also looked at basic fibroblast growth 
factor (bFGF), soluble intercellular adhesion molecule (ICAM) and E-selectin, both at 
baseline and during therapy. Baseline ICAM levels were shown to be prognostic but not 
predictive as patients on both arms with low baseline ICAM had a higher response rate 
and better OS (p = 0.00005) compared to those with high ICAM. In a NSCLC study of 
the VEGF receptor tyrosine kinase inhibitor (VEGFR-TKI) vandetanib, it was noted that 
VEGF levels predicted for PFS with lower levels associated with a better PFS.4 In other 
malignancies the role of baseline circulating VEGF-A is more promising as a predictive 
marker for bevacizumab benefit. In a large phase III gastric cancer trial of bevacizumab 
(AVAGAST), the investigators noted that high plasma VEGF-A levels were associated with 
a poor prognosis in all patients, but benefit from bevacizumab was more pronounced in 
those patients as well.5 A trend toward higher response and survival was seen with the 
addition of bevacizumab in patients with high baseline VEGF-A levels, but not in those 
with low levels. Similar differential survival benefit from bevacizumab was seen in both 
breast and pancreatic cancer patients with high, but not low, baseline plasma VEGF-A 
levels indicating the importance of further study of this biomarker. The technique used 
in those analyses, which quantifies soluble low molecular weight isoforms of VEGF-A, is 
the first truly predictive biomarker of bevacizumab activity, but these results have yet to 
be validated in other tumor types. The gastric trial also showed some potential predictive 
value with neuropilin-1 (low levels predicting for OS benefit). Genetic variants in VEGF 
pathway members have also been explored as potentially predictive biomarkers. A subset of 
patients with pancreatic or renal cell carcinoma enrolled on two separate phase III clinical 
trials of bevacizumab therapy were studied for single nucleotide polymorphisms (SNPs) 
in many genes related to angiogenesis. After investigating over 100 SNPs, a single SNP 
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in VEGFR-1 was significantly associated with PFS for patients receiving bevacizumab in 
both trials, and additionally OS in the pancreatic cancer study.6It is felt that this SNP leads 
to increased VEGFR-1 expression and subsequently to increased downstream VEGFR-1 
signaling. In E4599, SNPS in VEGF, VEGFR-1, ICAM-1, and epidermal growth factor 
were analyzed without a conclusive result, though one VEGF polymorphism did seem to 
correlate with survival.7 Further work on VEGF(R) SNPs continues. Investigators have also 
studied circulating endothelial cells, but as they are difficult to quantify and not clearly 
of predictive (rather than prognostic) value, it is unclear how far this field of research will 
develop. Profiling of multiple plasma markers has led to identification of marker signatures 
that have been associated with response to VEGFR-TKIs. In an analysis of 33 NSCLC 
patients treated with the VEGFR-TKI pazopanib, the cytokine and angiogenic factor 
(CAF) profiles were associated with tumor shrinkage. This was primarily true for changes 
in soluble VEGFR-2 and IL-4 and with baseline levels of IL-12 and hepatocyte growth 
factor (HGF).8 However, the cytokines of interest have been variable with other VEGFR-
TKIs in analyses by the same group.9,10 Ongoing clinical trials of anti-angiogenic agents 
must incorporate exploratory and confirmatory biomarker analyses to help reach better 
understanding. The adjuvant NSCLC bevacizumab trial E1505 is collecting tumor samples, 
as well as plasma and serum at baseline, during, and after completion of chemotherapy, and 
these samples should allow for validation of some of the biomarkers under investigation 
in an adjuvant NSCLC population. REFERENCES: 1. Rini BI, et al. J Natl Cancer Inst 
103:763-73, 2011 2. Dahlberg SE, et al. J Clin Oncol 28:949-54 3. Dowlati A, et al. Clin 
Cancer Res 14:1407-12, 2008 4. Hanrahan EO, et al. Clin Cancer Res 15:3600-9, 2009 5. Van 
Cutsem E, et al. J Clin Oncol 30:2119-27, 2012 6. Lambrechts D, et al. Lancet Oncol 13:724-
33, 2012 7. Zhang W, et al. J Clin Oncol 27:Abstract 8032, 2009 8. Nikolinakos PG, et al. 
Cancer Res 70:2171-9, 2010 9. Hanrahan EO, et al. J Clin Oncol 28:193-201, 2010 10. Zurita 
AJ, et al. Ann Oncol 23:46-52, 2012 
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CURRENT STATUS OF SURGICAL MANAGEMENTS FOR STAGE III 
LUNG CANCER IN JAPAN
Ichiro Yoshino1, Etsuo Miyaoka1, Hisao Asamura2, Yoshitaka Fujii3, Yoichi Nakanishi4, 
Kenji Eguchi1, Masaki Mori1, Noriyoshi Sawabata1, Meinoshin Okumura1, Kohei Yokoi1  
1Department Of General Thoracic Surgery, Graduate School Of Medicine, Chiba 
University, /JAPAN, 2Division Of Thoracic Surgery, National Cancer Center Hospital, 
Chuo-ku, Tokyo/JAPAN, 3Oncology, Immunology And Surgry, Nagoya City University 
Graduate School Of Medical Sciences/JAPAN, 4Research Institute For Diseases Of The 
Chest, Graduate School Of Medical Sciences, Kyushu University, Fukuoka/JAPAN
Backgrounds: Stage III lung cancer comprises heterogeneous subpopulations, and includes 
T factors such as extension to neighboring organs and pulmonary metastasis (pm), and N 
factor. Current status of surgical treatments for the stage III lung cancerf is analyzed using 
a data of the nationwide lung cancer registry. Materials and methods: From the central 
database of lung cancer patients undergoing surgery in 2004, which was founded by the 
Japanese Joint Committee of Lung Cancer Registration, data of interested populations of 
stage III patients were extracted, and the clinicopathologic profile of patients and surgical 
outcomes were evaluated. Results: 
•	Overall	survival	of	stage	IIIA/IIIB:	This registry comprises 11,663 cases of lung   
 cancer, who underwent surgery in 2004 in Japan. The 5-year survival rates (5-ysr) of   
 clinical (c)/pathological (p) stage IIIA and IIIB were 42.8%/40.9% (n=1216/1804) and   
 40.3%/27.8%(n=90/106), respectively (Sawabata et al. J Thorac Oncol 2011;6:1229-35). 
•	Stage	IIIA-N2: 436 cases with stage IIIA-cN2/pN2 non-small cell lung cancer were  
 collected from the mother database. They showed 82.5% of R0 surgery and 2.3% of  
 hospital death. The 5-ysr was 30.1% in total, and 34.0% in surgery alone (n=137) and  
 35.8% in single station N2 (n=235). There was no difference in survival data among  
 subpopulations classified by perioperative treatments (Yoshino et al. J Thorac Oncol  
 2012;7:850-5). 
•	T3-extension	to	neighboring	organs: 531 cases with T3 were collected, 351 (66%) of  
 which were N0 (stage IIB). Ro surgery was achieved in 461 cases (86.8%), and hospital  
 death was 3.2 %. Involved structures were chest wall in 407 cases (76.6%), mediastinal  
 pleura in 56 (10.6%), bronchus in 45 (8.5%), diaphragm in 31 (5.8%), and pericatdium  
 in 20 (3.8%). The 5-ysr were 44.9% in total, 47.5% in R0, 24.2% in R1/2, 50.6% in N0,  
 46.4% in N1 and 22.0% in N2. Survival was significantly superior in patients with  
 adjuvant chemotherapy (51.8% of 5-ysr) to those without adjuvant chemotherapy  
 (41.1%) (p=0.006) (Kawaguchi et al. J Thorac Cardiovasc Surg 2012;144:431-7).
Conclusions: The Nationwide registry data clearly exhibited modern surgical outcome of stage 
III lung cancer, and the results would suggest future directions of strategy against the diseases.
Keywords: LUNG CANCER, Surgery, stage III
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MINIMALLY INVASIVE SURGERY
Yi-long Wu  
Guangdong Lung Cancer Institute, Guangdong General Hospital And Guangdong 
Academy Of Medical Sciences, Guangzhou, Guangzhou/CHINA
Over the last 20 years thoracic surgeons developed a minimally invasive technique to 
provide the best treatment with minimal risk. VATS lung resection is slowly becoming 
the standard of care for patients with early stage lung cancer. A standardized definition of 
VATS was provided by the Cancer and Leukemia Group B, which conducted a prospective 
multi-institutional feasibility study of VATS lobectomy (CALGB 39802). The true 
VATS lobectomy was defined as a lobectomy performed with videoscopic guidance and 
anatomic hilar vascular, bronchial, and lymphatic dissection using two or three ports 
and without rib spreading. Advantages to the VATS approach compared with traditional 
open lobectomy are less morbidity and shorter hospitalization. The advantage was due 
to advances in anesthesia and technology. VATS provided both excellent exposure and 
superior visualization of the thoracic cavity. In 2009 Yan et al reported a meta analysis that 
showed there were no significant statistical differences between VATS and open lobectomy 
in terms of postoperative prolonged air leak (P = .71), arrhythmia (P = .86), pneumonia 
(P = .09), and mortality (P = .49). VATS did not demonstrate any significant difference in 
locoregional recurrence (P = .24), as compared with the open lobectomy arm, but the data 
suggested a reduced systemic recurrence rate (P = .03) and an improved 5-year mortality 
rate of VATS (P = .04).In our hospital—Guangdong Lung Cancer Institute from 2007 to 
2012—Thoracic surgical technique was developed from traditional open thoracic surgery to 
muscle-sparing minithoracotomy, then VATS to complete thoracoscopic surgery and now 
single hole thoracoscope operation. Our experiences also showed that several advantages of 
VATS or complete thoracoscopic surgery as below: less pain; little scarring; minimal blood 
loss; no cutting of the ribs; faster recovery and return to normal activities; shorter hospital 
stay; and possible improved cure rates for lung cancer.
Keywords: NSCLC, Surgery, Thoracoscopy, minimal invasion
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GENETIC MARKER FOR LUNG CANCER DIAGNOSIS- MOLECU-
LAR PROFILING OF ADENOCARCINOMA OF THE LUNG
Young T. Kim  
Department Of Thoracic And Cardiovascular Surgery, Seoul National University, Seoul/
KOREA
Recent success of targeted agent for the treatment of lung cancer has led a paradigm 
shift from the histology-based conventional treatment to the integrated molecular 
alteration-based strategy. Hence, the identification of the molecular events that drive 
cancer transformation is essential for the development of targeted agents and subsequent 
successful treatment of patients with lung cancer. We recently searched molecular 
alterations from a cancer tissue of 33-year-old lung adenocarcinoma patient, who showed 
no mutation in EGFR or KRAS and no EML4-ALK fusion. Using combined analysis of 
massively parallel whole-genome and transcriptome sequencing for cancer and paired 
normal tissue of the patients, we discovered a novel fusion gene between KIF5B and the 
RET proto-oncogene caused by a pericentric inversion of 10p11.22–q11.21. This fusion 
gene overexpressed chimeric RET receptor tyrosine kinase, which could spontaneously 
induce cellular transformation. Subsequently, such molecular alteration of KIF5B-RET 
fusion was reported by other investigators. We further analyzed 200 surgical specimens of 
lung adenocarcinoma in Koreans. After screening of EGFR and EML4-Alk mutation, we 
selected 87 double negative patients and performed transcriptome sequencing for deeper 
characterizations. Among them, we identified additional two patients who possessed 
KIF5B-RET fusion. We also discovered various driver mutations, including several novel 
drivers for lung adenocarcinoma. There were interesting observations between the number 
of somatic mutations, expression outliers and clinical characteristics. To set up a clinically 
useful method to detect KIF5B-RET rearrangement, we set up various diagnostic methods 
including fluorescence in situ hybridization (FISH), and immunohistochemistry (IHC), 
and PCR methods. Those methods were simultaneously applied on the paraffin embedded 
tissue slides, and DNA extracted from fresh frozen cancer tissue. For the molecular 
profiling of adenocarcinoma of the lung, we selected 520 adenocarcinoma patients and 
prepared DNA and tissue microarrays. Those were tested for various molecular alterations. 
Detailed data for the above-mentioned studies are still not ready for public release but will 
be presented during the meeting. In conclusion, our findings broaden our understanding 
of lung adenocarcinoma and may also lead to new diagnostic and therapeutic approaches. 
Keyword: mutations
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A NON-INVASIVE SYSTEM FOR MONITORING OF EGFR MUTA-
TION STATUS WITH PLASMA DNA
Tomomi Nakamura1, Naoko Sueoka-Aragane2, Kentaro Iwanaga3, Akemi Sato2, Komiya 
Kazutoshi2, Naomi Kobayashi2, Shinichiro Hayashi2, Eisaburo Sueoka2, Shinya Kimura2  
1Department Of Internal Medicine, Faculty Of Medicine, Saga University, Saga/JAPAN, 
2Saga University/JAPAN 3Saga Prefectural Hospital Koseikan/JAPAN
Background: Detection of EGFR mutations is indispensable to determine an appropriate 
lung cancer treatment. Although 70% of lung cancer patients with EGFR activating/
sensitive mutations benefit from EGFR tyrosine kinase inhibitor (EGFR-TKI), they 
eventually acquired resistance. Chemotherapy is selected after acquired resistance, and 
re-treatment of EGFR-TKI after chemotherapy is often effective. Considering some clinical 
trials for irreversible EGFR-TKI and MET inhibitors have been performed, these treatment 
strategies will be applicable near future. We have pursued the non-invasive monitoring 
system of EGFR mutation status using circulating plasma DNA. Methods: We established 
novel methods to identify EGFR mutations: wild inhibiting PCR and quenched probe 
system (WIP-QP) for exon 19 deletions, and mutation-biased PCR and quenched probe 
system (MBP-QP) for L858R and T790M. The detection systems includes fully automated 
genotyping, based on analysis of the probe DNA melting curve, which binds the target 
mutated site using a fluorescent guanine quenched probe (QP-system), combined with 
MBP or WIP for achievement of higher sensitivity these mutations. Results: Detection 
limit was 0.005-0.2 ng in genomic DNA, and 0.1-0.3% mutant plasmids. First, we examined 
DNA isolated from lung cancer specimens and circulating plasma DNA samples of 39 
adenocarcinoma patients whose primary tumors harbored EGFR exon 19 deletions or 
L858R. The results in cancer tissue specimens were identical to those with existing systems 
(nucleic acid-locked nucleic acid PCR clamp (PCR clamp) or cycleave PCR), except for two 
samples that showed mutations at both exon 19 deletions and L858R. Exon 19 deletions and 
L858R were detected in 44.7% and 8.7% of patients using plasma DNA among those who 
carried the identical mutations in primary tumors; all of those cases evidenced pathological 
stage IV except for one patient, suggesting that EGFR mutations might be preferentially 
detected in plasma DNA obtained from patients in advanced stages. As for investigation of 
T790M, sixty-seven plasma DNA samples from forty-nine lung adenocarcinoma patients 
and thirty healthy volunteers were evaluated. The T790M mutation was detected in 
plasma DNA from ten of nineteen patients (53%) who acquired resistance, but not in non-
responders, patients responding to treatment, or those not treated with EGFR-TKI. Other 
mutation detection systems, such as PCR clamp, the cycleave PCR technique, and allele-
specific oligonucleotide PCR, detected T790M in three, four, and six patients, respectively, 
among ten in which T790M was detected by the MBP-QP method. Serial monitoring 
of exon19 deletion, L858R and T790M demonstrated correlation with disease state. 
Conclusion: These monitoring systems are simple, sensitive, and—intriguingly—reflective 
of clinical course, which can be applicable for making decision of lung cancer treatment.
Keywords: plasma DNA, EGFR mutations, T790M
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CT SCREENING FOR LUNG CANCER
James L. Mulshine  
Internal Medicine, Rush University Medical Center, Chicago/IL/UNITED STATES OF 
AMERICA
In a display of clear international leadership, the Japanese government has committed to 
reducing national smoking rates to 12% by 2023. While saluting this critical goal, due to 
the nature of tobacco carcinogenesis, former smokers still experience an increased risk 
of developing lung cancer. However, lung cancer screening with low dose CT (LDCT) 
now provides a validated ability to reduce lung cancer mortality. In Japan, it is timely to 
consider that status of CT-based screening as a complementary measure to tobacco control 
in realizing maximal public health benefit in addressing tobacco-related deaths from 
cigarettes. Twenty years ago, the pioneering work of groups working with Professors C. 
Henschke, S. Sone and M Kaneko published pilot studies suggesting the utility of using 
spiral CT to detect early, curable lung cancer. These reports have now been validated by 
the findings of the National Lung Screening Trial (NLST) which found that LDCT was 
associated with a 20% reduction of lung cancer mortality compared to CXR screening. 
The authors of the NLST report noted that the complications of providing the screening 
services were modest. Of the 53,000 subjects participating in the NLST most of them came 
from centers that were not selected for excellence in lung cancer care. The majority of the 
NLST accrual occurred at centers that were involved in conducting a previous prostate 
cancer, colon cancer, ovarian cancer and lung cancer (PLCO) screening trial. These centers 
did not have a pre defined approach to screening diagnostic work-up or surgical care of 
screen-detected cancers. Also, since the NLST was started in 2002, most of the imaging 
was done on 4-detector, CT scanners. These are critical issues since there has been so 
much progress in screening management, minimally invasive thoracic surgery and CT 
imaging over the last decade. Therefore, there is objective basis supporting optimism that 
implementation of LDCT screening in high risk populations can at least achieve the level 
of subject benefit reported with the NLST. We performed an actuarial based analysis of 
LDCT screening based on using a best-practice approach to the clinical management 
from existing publications. We compared our LDCT findings to the established costs 
for other cancer screening services. From that analysis, the cost of cancer screening per 
life-year saved (projected to 2012 dollars using the US Consumer Price Index medical 
component) was $50,162 to $75,181 for cervical cancer, $18,705 to $28,958 for colorectal 
cancer, and $31,309 to $51,274 for breast cancer. In contrast for LDCT, the 2012 estimate 
for the cost per life-year saved was $18,862 for lung cancer. One of the critical elements of 
our analysis was the obligatory inclusions of tobacco cessation services for all screening 
participants. Smoking cessation is a well established public health approach. Since half of 
the potential high risk subjects that would be the target for LDCT are still smokers, this is 
an important consideration. Smoking drives the progression of not only lung cancer, but 
coronary artery disease and COPD. For maximal public health benefit to reduce premature 
mortality and achieve optimal cost economy, LDCT must be integrated with tobacco 
control measures. Since the LDCT screening subjects do come back at regular intervals, 
there is an opportunity to tailor the smoking cessation approach to improve on success rate 
with heavy chronic smokers. This is a good example on where ongoing research is essential 
to continue to improve outcomes with LDCT screening. In implementing LDCT, there 
are many other challenges and so to share best practice, an advocacy group has created a 
collaborative consortium for those interested in fostering optimal lung cancer screening 
approaches can interact (http://www.screenforlungcancer.org/national-framework/). This 
Framework approach attempts to build on the experience with other cancer screening 
sites to allow initial approaches to lung cancer screening to be more capable. Participation 
in this voluntary approach revolves around acceptance of core principles such as that the 
screening subject should expect certain factors. This is embodied in the “Rights of People” 
statement, which is provided below. 
•	You	have	the	right	to	know	if	you	are	at-risk	for	lung	cancer. 
•	You	have	the	right	to	know	that	well	organized	low	dose	CT	screening	has	been	shown	 
 to significantly reduce the possibility of dying from lung cancer. 
•	You	have	the	right	to	clear	and	unbiased	information	on	the	risks	and	benefits	of	CT	 
 screening. 
•	You	have	the	right	to	fair	and	equitable	access	to	medically	appropriate	CT	screening. 
•	You	have	the	right	to	timely	and	compassionate	care	if	you	are	diagnosed	with	lung	 
 cancer. 
•	You	have	the	right	to	donate	your	scans	and	biological	specimens	to	lung	cancer	 
 research to help find additional life saving cures. 
•	You	have	the	right	to	ask	screening	sites	if	they	follow	the	Guiding	Principles	for	Lung	 
 Cancer Screening Excellence and provide care in a multi-disciplinary continuum.
This approach attempts to educate the at-risk subject around the issues inherent in the 
decision to participate in LDCT and establish a “floor” of quality around the provision 
of screening services. Other aspects of the Framework approach relate to encouraging 
the use of evidence-guided clinical care involving algorithm based on I-ELCAP and 
other well established screening managment approaches. As this is a new service, there 
is a need to be dynamic about recommendations to ensure continuous improvement of 
screening approaches, but also a need to apply corresponding rigor with integration of new 
approaches when critical levels of evidence emerge. The Institute of Medicine has proposed 
an approach to the continuous refinement of clinical management in its numerous 
publications on the Rapid Learning Health System. The approach proposed by the IOM is 
to acquire relevant clinical data around a clinical service and then to analyze the outcomes 
in a way to allow continuous process improvement of the service. LDCT is an example 
where this approach can be applied and potentially allow for much safer, less intrusive and 
more economically screening approaches to emerge.
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LUNG CANCER SCREENING IN JAPAN
Motoyasu Sagawa  
Kanazawa Medical University, Kahoku-gun/JAPAN
Current Lung Cancer Screening Program in Japan In Japan, mass screening using chest 
roentgenogram had been conducted nationwide from the 1950s to detect patients having 
pulmonary tuberculosis. In the last several decades, the objective of screening has been 
changed to the detection of early lung cancer. The lung cancer screening performed in 
Japan is a combination approach of chest roentgenogram for all subjects (40 years of 
age and older) and sputum cytology for the high-risk group (50 years of age and older 
AND 30 pack-years and over). The screening interval is once a year. The interpretation 
of the images is performed by two physicians independently (double interpretation). The 
films on the previous screening visits of the screenee, who is suspected to have abnormal 
pulmonary shadow by the double interpretation, are collected and compared (comparative 
interpretation). Sputum cytology (collected over a 3-day period) is conducted by a 
screener who has been certified by the Japanese Society of Clinical Cytology. In 2010, 
about 6,800,000 people participated in lung cancer screening in Japan. Efficacy of Lung 
Cancer Screening The efficacy of lung cancer screening is still controversial. Many studies 
have shown that the prognosis of the screening-detected patients is better than that of 
the symptom-detected patients with a significant difference. However, it has been found 
that such studies do not prove screening efficacy at all, because there are several types 
of biases (lead-time bias, length bias, overdiagnosis bias, etc.). Although randomized 
controlled trials conducted in the 1970s had failed to prove the efficacy of lung cancer 
screening, four Japanese case-control studies, conducted in the 1990s and published in the 
early 2000s, indicated that the current lung cancer screening program can decrease the 
risk of death from lung cancer by 30 - 60%. However, based on a subanalysis, it was also 
revealed that the effect of lung cancer screening persists only for one year. Therefore, we 
need to be fully aware that missing one screening would lead to the loss of a chance of a 
cure. Recently, the result of PLCO trial was reported, in which annual chest radiographic 
screening for 3-4 years did not have any effect on cumulative lung cancer mortality during 
a 13-year follow-up. However, the trial ignores important points that should be discussed. 
The results of PLCO trial show that lung cancer mortality in the intervention group was 
apparently smaller than that in the control group in the early period (7-8 years from the 
randomization), but this tendency disappeared later. This seems to be a natural outcome, 
because screenings were performed for only first 3-4 years in 13 years and the sojourn 
time of lung cancer was reported to be only 1-4 years. The relative risk during 5 years in 
PLCO trial was 0.89, which was regarded as being considerably low, because the PLCO 
trial had planned to detect a relative risk of 0.90. Thoracic CT Screening for Lung Cancer 
In introducing thoracic CT for lung cancer screening, exposure to X-rays was a major 
problem. In order to solve that, low-dose CT began to be developed and applied in practice, 
mainly in Japan. The results of lung cancer screening with low-dose CT were reported from 
the Anti-Lung Cancer Association (Tokyo), Sinshu University (Nagano), and ELCAP (New 
York), leading to a focus on low-dose CT as the next-generation method for lung cancer 
screening. According to the report of the Japanese Society of CT Screening, about 95,000 
people participated in the thoracic CT screening in 2006. When screening is performed 
via thoracic CT, a lot of shadows are detected. In this era of the multi-detector, a larger 
number of shadows have come to be detected. Conducting a detailed examination for all of 
them increases the detriments, i.e., unnecessary further examination to the false positive 
cases. Many studies have been conducted with respect to how to manage detected shadows. 
Especially in Japan, because a large number of shadows of small ground glass opacity 
(GGO) were detected, clinical and pathological studies thereof have been conducted early. 
As a result, it has been revealed that pure GGO tumors would be highly likely to be very 
slow-growing, even if it is lung cancer. Observing this without treatment is one option. On 
the basis of these results, the Japanese Society of CT Screening has made an algorithm for 
the management of detected shadows on Web site. Efficacy of Thoracic CT Screening As 
described above, in the low-dose thoracic CT screening for lung cancer, the detection rate 
of lung cancer, the percentage of early cases of detected lung cancer, and the survival rate 
of detected lung cancer are all surprisingly high. However, due to the biases mentioned in 
the previous section, it is impossible to prove the presence or absence of effects only with 
a comparison of the survival rate and the detection rate. It is necessary to verify whether 
lung cancer mortality caused in certain populations has been reduced or not. In 2010, the 
results of NLST trial was reported, in which annual low-dose thoracic CT lung cancer 
screening for 3 years decreased lung cancer mortality by 20% than chest XP screening 
in smokers (over 30 pack-years). Although the test positive rate was considerably high 
in NLST trial, that in NELSON trial being conducted in Europe is planned to be lower. 
However, both of the two trials focused to the efficacy in smokers. In Japan, it is considered 
that the efficiency of mortality reduction of thoracic CT screening in non-smokers might 
be higher than that in smokers. With the budget from the Ministry of Health, Labor and 
Welfare of Japan, a randomized controlled trial is now being conducted in non-smokers/
smokers under 30 pack-years (JECS Study: The Japanese randomized trial for evaluating 
the Efficacy of low-dose thoracic CT Screening for lung cancer).
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ADJUVANT CHEMOTHERAPY FOR NON-SMALL LUNG CANCER; 
JAPANESE EXPERIENCE
Nobuyuki Yamamoto  
Shizuoka Cancer Center, Shizuoka Prefecture/JAPAN
Based on several landmark studies and meta-analyses, the standard of care for stage II - III 
A non-small cell lung cancer (NSCLC) patients has been adjuvant cisplatin-based doublet 
chemotherapy performed after appropriate surgical resection. The benefit of this therapy 
for patients with stage I B NSCLC is less apparent, likely because of the heterogeneity of 
this population. In Japan, however, based on phase III studies conducted in Japan and 
a meta-analysis, postoperative adjuvant chemotherapy with tegafur-uracil (UFT) has 
become the standard of care for patients with completely resected stage I NSCLC (>2cm). 
Now, several adjuvant phase III studies have been launched such as UFT versus tegafur-
gimeracil-oteracil potassium (TS-1) for resected stage I NSCLC, Gefitinib versus Cisplatin 
+ Vinorelbine for resected stage II-III NSCLC harboring EGFR mutation and Cisplarin 
+ Pemetrexed versus Cisplatin + Vinolrelbine for resected stage II-III NSCLC with EGFR 
wild type. I would like to introduce the experience of our adjuvant chemotherapy and 
above new studies. 
